Full text is available at the source.
Lipid nanoparticles for engineering next generation CAR T cell immunotherapy
Using lipid nanoparticles to improve CAR T cell cancer treatment
AI simplified
Abstract
Lipid nanoparticles (LNPs) may enhance the production process of chimeric antigen receptor (CAR) T cells.
- LNPs can activate T cells and deliver the CAR transgene simultaneously, potentially streamlining CAR T cell production.
- Current CAR T cell production methods have limitations that LNPs could help to address.
- The review highlights recent advancements in LNP designs aimed at improving CAR T cell therapy.
- Safety, immunogenicity, scalability, manufacturing, and regulatory considerations are crucial for the clinical application of LNP-based CAR T cell therapies.
AI simplified